All In Biotech

NDA 216675 · Bausch and Lomb INC

Miebo

Perfluorohexyloctane · Ophthalmic · Semifluorinated Alkane

Novel

CDER novel approval, May 18, 2023: To treat signs and symptoms of dry eye disease

Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 18, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

15

4 Phase 3, 0 recruiting

FAERS reports

2,325

761 serious, 166 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 10, 2026.

MIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for treatment of the signs and symptoms of dry eye disease. ( 1 )

Mechanism: Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is not known.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 18, 2023 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • MIEBO · PERFLUOROHEXYLOCTANE 1.338GM/ML · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Perfluorohexyloctane" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • inappropriate schedule of product administration328
  • eye pain307
  • eye irritation297
  • vision blurred275
  • product use issue240
  • product delivery mechanism issue201
  • drug ineffective177
  • circumstance or information capable of leading to medication error170
  • product use complaint164
  • ocular hyperaemia159
  • death158
  • dry eye154

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20213
202210
202366
2024398
2025926
2026922

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Miebo (Perfluorohexyloctane/PF)

2024 spending

$116M

Beneficiaries

48,590

134,845 claims

Per beneficiary

$2,394

$246.59 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$9,327,677
2024$116,305,942

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 20 on PubMed

Sponsor: Bausch and Lomb INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.